A unique collection of 2112 kinase inhibitors for high throughput screening and high content screening for drug discovery in kinase related diseases;Bioactivity and safety confirmed by pre-clinical research and clinical trials, and some of them are approved by FDA;Targets include MAPK, PI3K, JAK, STAT, CDK, MEK, Insulin/IGF receptors, CaM Kinease II, PKA, JNK, PKC, RAF, EGFR, SAPK, GSK, MLCK, Src-family, IKK, PDGFR, VEGFR, etc;Detailed compound information with structure, target, activity, IC50 value, and biological activity description;Structurally diverse, medicinally active, and cell permeable;NMR and HPLC validated to ensure high purity and quality;